Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center Randomised Open-Label Phase 2 Study to Assess the Safety, Tolerability and Efficacy of Fimaporfin-Induced Photochemical Internalisation of Gemcitabine Complemented by Gemcitabine/Cisplatin Chemotherapy Versus Gemcitabine/Cisplatin Alone in Patients With Inoperable Cholangiocarcinoma

NCT04099888 is registered in ClinicalTrials.gov with PCI Biotech AS as lead sponsor.

NCT NCT04099888
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04099888 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center Randomised Open-Label Phase 2 Study to Assess the Safety, Tolerability and Efficacy of Fimaporfin-Induced Photochemical Internalisation of Gemcitabine Complemented by Gemcitabine/Cisplatin Chemotherapy Versus Gemcitabine/Cisplatin Alone in Patients With Inoperable Cholangiocarcinoma
Lead sponsor
PCI Biotech AS
Phase
Phase 2
Overall status
Terminated
Start date
May 23, 2019
Completion date
May 6, 2022
Enrollment
41 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

cholangiocarcinoma